Table 1.
Patient characteristics in all patients together and in the 2 cohorts
| Characteristic | All n = 131, n (%) |
Patients sampled at diagnosis n = 81, n (%) | Patients sampled at relapse n = 50, n (%) | OS HR∗, n (%) | |
|---|---|---|---|---|---|
| sCD163 (ng/mL)† | 3112 (1223-7611) | 3211 (1311-7611) | 2963 (1223-6002) | 3.8 (1.9-7.5)‡ | |
| Dx period | 2002-2015 | 59 (45) | 33 (41) | 26 (52) | ref |
| 2016-2020 | 72 (55) | 48 (59) | 24 (48) | 0.7 (0.39-1.3) | |
| Age | < 70 | 70 (53) | 42 (52) | 28 (56) | ref |
| ≥70 | 61 (47) | 39 (48) | 22 (44) | 1.4 (0.83-2.5) | |
| Sex | Female | 36 (27) | 22 (27) | 14 (28) | ref |
| Male | 95 (73) | 59 (73) | 36 (72) | 1.5 (0.76-3) | |
| ECOG | 0-1 | 83 (97) | 77 (96) | 6 (100) | ref |
| 2-4 | 3 (3.5) | 3 (3.8) | 0 (0) | 3.7 (0.88-16) | |
| Unknown | 45 | 1 | 44 | ||
| MIPI | 1 | 21 (17) | 11 (14) | 10 (20) | ref |
| 2 | 52 (41) | 35 (45) | 17 (34) | 3.2 (1.0-10.8) | |
| 3 | 54 (43) | 31 (40) | 23 (46) | 4.8 (1.4-15.8) | |
| Unknown | 4 | 4 | 0 | ||
| LDH | Normal | 70 (55) | 45 (57) | 25 (52) | ref |
| High | 57 (45) | 34 (43) | 23 (48) | 2.0 (1.2-3.5) | |
| Unknown | 4 | 2 | 2 | ||
| Hb | Normal | 70 (56) | 41 (55) | 29 (58) | ref |
| Low | 54 (44) | 33 (45) | 21 (42) | 3.3 (1.8-6.3) | |
| Unknown | 7 | 7 | 0 | ||
| Ki-67 | <30% | 27 (39) | 14 (45) | 13 (34) | ref |
| ≥30% | 42 (61) | 17 (55) | 25 (66) | 1.7 (0.76-3.6) | |
| Unknown | 62 | 50 | 12 | ||
| Histology | Classic | 52 (76) | 27 (84) | 25 (69) | ref |
| Blastoid | 16 (24) | 5 (16) | 11 (31) | 2.1 (0.9-4.8) | |
| Unknown | 63 | 49 | 14 | ||
| p53 or TP53 | Low or no mutation | 61 (79) | 24 (83) | 37 (77) | ref |
| High or mutated | 16 (21) | 5 (17) | 11 (23) | 2.2 (0.99-4.8) | |
| Unknown | 54 | 52 | 2 | ||
The patients sampled at diagnosis were treated with rituximab (R) and bendamustine (n = 33), the Nordic MCL 2 protocol with induction cytarabine-based chemotherapy and consolidation with high-dose chemotherapy with an autologous stem cell transplantation (n = 19), ibrutinib (n = 7), R-CHOP (R-cyclophosphamide, doxorubicin, vincristine and prednisone) (n = 3), rituximab only (n = 4), watch and wait (n = 1), or R-cytarabine (n = 1). For 13 patients the treatment was unknown. Patients from the clinical trial cohort were treated with rituximab, ibrutinib and lenalidomide within the trial. The 6 patients with MCL who relapsed from the Uppsala cohort were previously treated with in median 1 prior treatment (range 1-3), and after inclusion in this study they received bendamustine (n = 2), ibrutinib (n = 1), venetoclax (n = 1), Nordic MCL 2 protocol (n = 1), and cyclophosphamide (n = 1). Three of the patients received ibrutinib and 1 received venetoclax in later courses.
Univariable Cox PHs for all patients, showing change in OS rate by clinical or biological characteristic compared with its reference value, have been presented.
Boldface indicates statistically significant values.
Dx period, diagnostic period; ECOG, Eastern Cooperative Oncology Group performance status scale; LDH, lactate dehydrogenase; MIPI, mantle cell lymphoma international prognostic index; ref, reference.
Univariable Cox PHs (95% CI) for OS.
Median (minimum-maximum); n (col %).
HR for OS, sCD163 dichotomized by median.